Comparative Effects of Sertraline and Nortriptyline on Body Sway in Older Depressed Patients Fouzia Laghrlssi-Thode, M.D., Bruce G. Pollock, M.D., Ph.D., Mark Miller, Ph.D., Linda Altieri, M. S.N., DavidJ. Kupfer, M.D. This study examined effects of nortriptyline and sertraline on the balance and stability ofdepressedgeriatric inpatients. Body sway was measured with a stableforceplatform at three timepointsi before starting antidepressant medication, 5-7 days after medication was initiated, and 1 week later. A group of healthy, unmedicated older volunteers was evaluated under the same conditions as patients. In sertraline-treatedpatients (n = 10), significant differences (P < 0.05) between baseline and the first week of treatment were found in the forceplatform measurements of sway length (L) and area of the center a/pressure (Ao), with patients' eyes both open and closed. This change in postural stability occurred in the absence of orthostatic bypotension. By the second uieel« .01 treatment, neither variable was found to be significantly different from baseline. In the nonmedicated volunteers (n = 20) and in the group ofpatients receiving nortriptyline (n = 11), no significant changes in postural stability were found. (American Journal of Geriatric Psychiatry 1995; 3:217-228) F alls t because of their frequency and their physical, psychological, and socioeconomic consequences, are a major public health problem in older people. An estimated 6%-10% offalls result in serious complications, such as hip fracture or sub- dural hematoma.Y' These injuries and their fatal complications are the sixth leading cause ofdeath in persons over the age of 65. 4 Even falls that do not result in serious injury may bring about a loss of confidence, with self-imposed activity re- Received September 7, 1994; revised December 14, 1994; accepted January 10, 1995. From the Department of Psychiatry. University of Pittsburgh School of Medicinc, Western Psychiatric Institute and Clinic, Pittsburgh, PA. Address correspondence to Dr. F. Laghrissi.. hode, Western Psychiatric Institute and Clinic, 3811 O'Hara T Street, Pittsburgh, PA 15213. Copyright © 1995 American Association for Geriatric Psychiatry THE AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY 217 Sertraline and Nortriptyline strictions leading to further debilitation. 5t6 Medications and psychotropic drugs, in particular, contribute to instability and increase the risk of falls among older people. 7- l O This risk is present even after controlling for confounding factors, such as confusion, dementia, and depression.'t 10 More specifically, antidepressants have been related to the incidence of falling, even after age, fall history and use of other psychotropic medication are controlled. l 1 Older patients treated with tricyclic antidepressants have been found to be at greater risk of hip fracture than unmedicated matched control subjects.i The mechanism by which antidepressants contribute to falls remains unclear. Possible contributing factors are orthostatic hypotension, sedation, extrapyramidal side effects, and impaired neurophysiologic ability to compensate for changes in postural stability METHODS We undertook an open comparative study to determine whether or not antidepressant drugs affect postural stability in older depressed patients. The subjects were inpatients on the Geriatric Clinical Research Unit of Western Psychiatric Institute and TABLE1. o o Clinic, in Pittsburgh, PAl Patients had been diagnosed as suffering from a major depressive episode and were starting antidepressant treatment with either nortriptyline or sertraline. Patients' inclusion in this study did not affect or interfere with any aspect of their care, including choice of antidepressant drug, which remained the decision of patients' own physicians. Any patient who could not stand alone for 5 minutes or could not keep his or her eyes closed for 20 seconds was excluded. In order to determine whether the variability observed among patients differs from nonpatlents, a group of 20 healthy, older volunteers was evaluated once per week for 3 consecutive weeks under the same conditions as the patients. These healthy volunteers took no psychotropic or cardiovascular medication during the entire study period. Each subject gave written informed consent for participation in this study. The most common method used to quantify body sway is a balance platform. 12- 14 This noninvasive tool consists of an array of sensors that are scanned by a computer to obtain the position of the center of force when the subject stands on the platform. An AMTI (Advanced Medical Technology; Inc.; Newton, MA)15 force-platform (Model OR6-5) was used to measure two force components of Demographic and clinical characteristics of untreated (control) subjects, sertrallne-, and nortriptyline-treated patients Control 20) (n Mean age, years Gender, MIW Race, white/other Weight, pounds Height, inches Mean dose, Week 1 mglday Week 2 = 75.3 ± 4.1 10/10 18/2 145 ± 16 64.8 ± 4.2 None None Sertraline (n = 10) 72.4 ± 6.9 3n 9/1 144 ± 18 67.2 ± 3.4 66.6 ± 33 102.7 ± 8 NortriptyUne (n = 11) 73.0 3/8 7/4 147 63.0 52.2 57.7 Statistic ± 4.8 O.79'J. 0.22 3 ± 28 ± 5.5 ± 20 ± 16 O.7S b O.06b All statistical values arc nonsignificant. a Fisher's exact test (one-tailed). b r-test, Note: 218 VOLUME 3 • NUMBER 3 • SUMMER 1995 0 Laghrlssi-Thode et all body sway in the lateral and sagittal planes concomitantly This force-platform was connected to a personal computer via an analog/digital converter. The mean position of the center of pressure relative to the platform coordinates was calculated by CAS (Computer-Automated Stability Analysis) software,15 and the sway data were plotted relative to this mean position. Hufschmidt et al. 16 examined the relative value of 13 different indices derived from platform recording for application in neurological diagnoses. They found the most useful measures to be the mean amplitude, the length of path of the center of pressure (L), and the area included within the path of the center of pressure (Ao). TABLE2. Psychiatric diagnosis (DSM-III-R), current medical illnesses, and patients with history of faU in the sertraUne and nortriptyline groups, " Sertraline (II Psychiatric diagnosis (n) =10) Nortriptyllne (II = 11) M.RoD. a (6) M.R.D. (4) MoR.Do b (3) M.D.Eo e (1) 1 M.RoD.b (6) Bop.d (1) 2 Patients with history of fall 2 Hypertension Ischemic heart 0 disease Arrhythmia 1 Hypothyroidism 1 Diabetes 1 Arthritis ,3 Emphysema 0 Chronic. constipation 2 Prostatic hypertrophy 1 1 Glaucoma Cataract 2 1 Seizure 3 4 4 0 3 1 3 1 1 3 3 1 0 a Major recurrent depression, severe, without gSfchotic features. Major recurrent depression, severe, with psychotic features. C Malordepressrve episode, single, moderate. d Bipolar disorder, depressed, moderate. Vissier17 has reported that the sway path is probably the most useful index of sway The author argues that the parameter of length would offer a greater potential than that of area in describing sway Length appears to more adequately take account ofdynamic action than does area because a large amount of sway may occur within a restricted area. 12 Other parameters, such as radial area, elliptical area, and root mean-square displacement of the center of pressure, are highly dependent on use ofa single-leg stance, and it has been concluded that such measures are not necessary in a protocol restricted to double-leg stance." For the safety of the patients, our study was restricted to double-leg stance rather than single-leg stance; therefore the length of path of the center of pressure (L, in em) and the area included within the path of the center of pressure (Ao, in sq. cm) were selected to quantify body sway The patients were evaluated on 2 consecutive days at three timepoints: before starting antidepressant medication (at baseline), 5-7 days after the medication was initiated (Week 1), and 1 week later (Week 2). To avoid the issue of diurnal variation of body sway; the patients were all evaluated at approximately the same time ofday The dose of medication was held constant from baseline to Week 1 and from Week 1 to Week 2. Balance evaluation was performed before dose adjustment at Week 1. Each patient was measured in double-leg stance on the force-platform, with feet together, looking straight ahead, focusing on an object at a distance of 3· meters, and with arms by their sides. Because body sway is greater with eyes closed than with eyes open, the subjects were evaluated with their eyes open and then closed. Three consecutive trials were made for each stance, and the measures were averaged for each subject. Each trial was recorded for 20 seconds. To determine whether or not the ef- THE AMERICAN JOURNAL OF GERIATIUC PSYCHIATRY 219 Sertraline and Nortriptyline FIGURE 1. Increase in length of sway path (L, in em) of older, depressed patients during the f"trst 2 weeks of treatment with sertraline (mean ± SD) fects of antidepressants on body sway occurred independently of blood pressure changes, blood pressure and pulse were measured before each evaluation, after 5 minutes supine, and for the first 3 mlnutes in the standing position. The following variables were recorded: age, gender, race, height, weight, psychiatric diagnosis (by DSM..III-R), active medical problems, ambulatory condition, medical history; and history of falls. All medications taken by the patient during the study period and in the preceding 2 weeks were recorded, as well as the type and daily dose of antidepressant. Data were analyzed using SAS software (version 6.06; SAS Institute Inc" Cary; NC). A repeated-measures. analysis ofvariance (ANOVA) model with planned comparisons was used to examine the 220 pairwise differences between baseline, Week 1, and Week 2 of treatment. The model used three main effects: week, 'da}', and trial. Two analyses were run for each group: one for the data recorded when subjects had their eyes open, and one for data recorded when subjects had their eyes closed. The data from the three groups were not normally distributed; therefore, sta.. tistical analyses were performed on the square-root transformation of the length of path of the center of pressure (L) and the area included within the path of the center of pressure (Ao). A one-way, repeated-measures ANOYA model was used to determine the interindividual variability among the three trials with eyes open and the three trials with eyes closed. VOLUME 3 • NUMBER 3 • SUMMER 1995 Lagbrissi-Tbode et ale FIGURE 2. Length of sway path (L, in em) with eyes open for individual subjects treated wtth sertraUne L (em) 200 180 -f- Patient #4 -IE- 160 Patient #1 Patient #13 --- Patient #14 140 -No- Patient #15 -+- Patient #19 -.- Patient #20 100 -I- - 80 Patient #22 Patient #25 -.- Patient #34 60 40 0 1 Week RESULTS In all, 20 healthy, older volunteers, 11 older, depressed patients treated with nortriptyline, and 10 older, depressed patients treated with sertraline completed this study. There were no statistical differences among the three groups regarding their demographic and clinical characteristics (Table 1). The psychiatric diagnoses (DSM-III-R), intercurrent illnesses, THE AMBRICAN JOURNAL OF GEIUATRIC PSYCHIATRY 2 and prior fall. history of the antidepressant-treated patients are presented in Table 2. All medication taken by the patients during the study period and in the preceding 2 weeks are reported in Table 3. In sertraline-treated patients, postural sway increased whether subjects had their eyes open or closed. This increase was statistically significant, and the planned comparison indicates that the significant difference for the variable L was between baseline and Week 1 (eyes 221 Sertraline and Nortriptyline TABLE 3. Concomitant treatment ofsertrallneand nortriptyUne-treated patients during the study period and in the preceding 2 weeks, 71 Sertraline (II 10) Norbiptyline 0 4 1 1 3 = Calcium channel blockers Diuretics Angiotensin converting enzyme inhibitors Nitroglycerin Insulin Levothyroxine sodium Atropine eye drops Cholinesterase inhibitor eye drops Vitamin 812. C. or E 0 1 (II = 11) 1 1 0 0 3 2 1 1 1 2 2 = open, P 0.004; eyes closed, P = 0.005; Figure 1). By the second week of treatment, sertraline tended to increase L,but this increase failed to achieve statistical significance between baseline and Week 2 (eyes open, P 0.202; eyes closed, P = 0.205). Figures 2 and 3 display individual changes in L with eyes open and closed over the 2 weeks of treatment with sertraIine. The Ao of the sertraline group (Figure 4) was comparable to the Ao of the untreated group (Figure 5) at baseline. After 1 week of treatment, sertraline significantly increased the variable Ao (eyes open, P = 0.014j eyes closed, P = 0.006). After 2 weeks of treatment, however, the increase inAo was not statistically different from baseline (eyes open, P = 0.222; eyes closed, P = 0.219). Changes in postural stability occurred in the absence of orthostatic hypotension and were clinically noticeable in five patients (#1, #4, #13, #22, and #34). Three patients (#1, #13, and #22) spontaneously complained of dizziness after the first week of treatment. Two other patients (#4 and #34) were not aware of their body sway changes with eyes open = 222 and reported unsteadiness only during the Romberg test with their eyes closed. No falls were observed during the study period. In the group of patients receiving nortriptyline, no significant changes in any of the two variables were found (P < 0.3; Figure 6). The body sway of these patients remained comparable to the sway of the untreated subjects (Figure 7). Individual measures of Land Ao did not differ from each other. No significant variation was found among the three trials with eyes open (P ~ 0.7) as well as among the three trials with eyes closed (P ~ 0.5). DISCUSSION The prevalence of drug-induced falls in older people and the association between falling and impaired balance has led to the development of the concept of body sway as a measure of drug effects. Increased body sway is associated with an increased risk of falling. I 9-22 This falling may result from impaired postural control and impaired corrective responses once balance is lost. Previous studies23- 26 have examined the effects of psychotropic medications on body sway and have pointed out that benzodiazepines (diazepam, lorazepam), potent HI antihistaminic compounds (chlorpheniramine, diphenhydramine), and anticonvulsant medications (phenytoin, meprobamate, amylbarbitone) consistently increase body sway. In contrast, psychostimulant compounds (caffeine, dexamphetamine, hydergine) showed no significant effect on sway.27 However, most ofthese studies have been conducted on healthy, young subjects after a single, oral dose. Dizziness and vertigo are common side effects ofantidepressant drugs. How.. ever, instability is rarely quantified, and objective measurement of body sway remains primarily research based. Use of tricyclic antidepressants (TCAs) is comVOLUME 3 • NUMBER 3 • SUMMER 1995 Lagbrhs~7bodeetal monly recognized to increase the risk of falls and hip fractures in older patients. In contrast, little is known about the use of selective serotonin reuptake inhibitors (58RIs) in older patients despite their increased use in this group. Unlike the TeAs, 55RIs are not associated with seda.. tion, significant anticholinergic effects, cardiac conduction changes, or orthostatic hypotension. Therefore, they may be considered to be a safer treatment, particularly for the medically compromised geriatric patient. However, a recent study (Ruthazer and Lipsitz 1 !) noted that among elderly; institutionalized women receiving antidepressant treatment, a larger percentage of those taking SSRIs fell, compared with those taking TeAs (53% vs, 14%; ratio 9/17 vs. 5/35; P = 0.003). These authors did not specify which 55RIs were studied and did not find a relationship between SSRIsand falls in men. According to our findings, one way by which SSRIs might increase the risk of falling in older patients is balance impairment. The underlying mechanism of such impairment is unclear. The main sensory systems involved in control- FIGURE 3. length of 8'vay path (L t in em) with eyes closed for individual subjects treated with sertraUne L (em) 200 180 - Patient#1 -f- Patient#4 160 -- Patient #13 --- Patient #14 140 -H- -+- 120 Patient #15 Patient #19 ........ Patient #20 100 --- Patient #22 ..... Patient #25 80 -.- Patient#34 60 40 0 1 Week THE AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY 2 223 Sertraline and Nortriptyline FIGURE 4. Increase of the area included within the path of the center of pressure (Ao, in sq. em) of older, depressed patients during the first 2 weeks oCtreatment with scrtraUne (mean ±SD) ling the body's center of gravity are proprioception, enteroception, vision, and the vestibular system. The afferent pathways involve the spinal cord, brain stem, cerebellum, midbrain, and sensory areas of the cortex. Interference with any of these pathways may therefore result in an increase in body sway SSRIs could affect these pathways at three levels: basal ganglia, vertebrobasilar blood flow; and cerebellum. 24 Bouchard et al. 28 reported an increased risk of extrapyramidal symptoms during treatment with fluoxetine, They suggested that this effect might arise through SSRI-mediated inhibition of dopamine production or through release by neurons of the basal ganglia. Older patients with age-related dopamine neuronal degeneration are probably more sensitive to this decrease of dopamine availability and may not be able to compensate as rapidly for this 224 impairment. Baldessarini and Marsh 29 tested this hypothesis in a laboratory model and concluded that fluoxetine moderately, but significantly; inhibited acute synthesis of dopamine in several areas of the mammalian forebrain. These effects appeared to persist or even to increase in the hippocampus and striatum. Recent data30 suggest the possibility that serotonergic projections from the raphe nuclei to the midbrain and basal ganglia can inhibit dopamine neurons, thus de.. creasing dopamine availability at their terminals by a 5-HTz-mediated synaptic mechanism. Sertraline does not block dopamine receptors but is unique among antidepressants at blocking uptake of dopamine into rat brain synaptosomes. 3 1,32 It is not known whether sertraline's potency is sufficient to affect dopamine uptake in vivo. Recent studies33t34 point out that diz .. ziness in older patients is often provoked VOLUME 3 • NUMBER 3 • SUMMER 1995 Lagbrlss~7bodeetaL by disorders of the autoregulatory mechanism of the cerebellar blood flow This suggests an important contribution of vertebrobasilar ischemia to dizziness. Serotonin is a potent vasoconstrictor that may reduce the vertebrobasilar flow The consequence of such reduction may not be clinically relevant in younger patients with adequate vascular autoregulation and compensatory mechanisms. Further research is needed to elucidate SSRIs' effects on cerebellar blood flow In the molecular layer of the cerebellum, 5-HTI-B serotonin receptors have been found, and 5-HT2 serotonin receptors have been described in the inferior olive. 35 In thiamine-deprived animals, a specific serotonergic cerebellar syndrome includes a selective degeneration of the serotonergic cerebellar systems and an exaggerated serotonergic tumover. 35 In human cerebellar cortical atrophy; comparable serotonergic disturbance has been observed in the cerebro- spinal fluid. 36 The effects of SSRIs on the serotonergic cerebellar systems are unknown. Therapeutic results have been obtained with L-5-HTP in patients with cerebellar cortical atrophy; therefore it is possible that 55RIs may also improve these patients. Alternatively SSRIs may deplete the serotonergic cerebellar neurons by blocking serotonin reuptake and result in a cerebellar syndrome analogous to thiamine deprivation in animals. CONCLUSION Sertraline caused an acute significant change in body sway in older, depressed patients with their eyes both open and closed. This change in balance happened after 1 week of treatment and did not appear to be dose dependent. By the second week of treatment, the increase in body sway failed to achieve significance. Apparently the patients compensated for FIGURE 5. Area Included within the path of the center of pressure (Ao, in sq. em) of healthy, untreated (control) subjects THE AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY 225 Sertraline and Nortriptyline the drug-induced impairment of their body sway during the second week of treatment despite sertraline dose increase. The increase of body sway may have failed to achieve significance at Week 2 because of the limited number of patients. Perhaps more sensitive measures, such as single-leg stance, would have yielded greater statistical significance. Despite the absence of clinical .and demographic differences between the sertraline and nortriptyline groups, the interpretation of the current data should be tempered by the fact that patients were not strictly randomized. In. order to confirm the results and determine whether other SSRIsaffect body sway, we are continuing to evaluate patients during double-blind therapy with nortriptyline vs, SSRIs. Further prospective controlled studies looking at the association between the use of SSRIs and risk of falls are also needed. In FIGURE 6. 226 the current study, nortriptyline did not increase instability in older patients despite its greater tendency to induce sedation and its anticholinergic and orthostatic-hypotensive effects. Miller et al.37 reported a decrease in subjective complaints of dizziness in older, depressed patients after nortriptyline treatment of underlying depression. Like other somatic complaints in depressed patients, dizziness may be erroneously attributed to medication side effects. Objective measurement with the force-platform quantifies the body sway and may clarify the relationship between the subjective complaint ofdizziness and the use of antidepressants. Our unexpected finding, that sertraline acutely impairs the balance of older patients, highlights the fact that medications are frequently introduced in older populations on the assumption that their side-effect profiles Length of sway path (L, in em) of older, depressed patients during the rust 2 weeks of treatment with nortriptyUne VOLUME 3 • NUMBER 3 • SUMMER 1995 "Lagbrissi-Tbode et ale FIGURE 7. Length of sway path (L, in em) ofhealtlty, untreated (control) subjects match those obtained in younger patients. Using newly introduced medications without first identifying those that have the potential to induce gait instability and falls in older patients may be particularly injudicious. Because of the high risk of falling identified in epidemiologic studies, it would seem prudent for geriatric psychiatrists to examine the postural stability of patients by means of a simple clinical procedure such as a Romberg test before starting such patients on SSRI medications. Note: Data in this article were presented in part at the New Investigator Awardee Poster Session, 34th Annual Meeting of the New Clinical Drug Evalu- ation Unit of the National Institute of Mental Health, Marco Island, PL, May 31, 1994. The authors thank the medical and nursing staffofthe Geriatric Clinical Unit; in particular, Benoit H. Mutsant, M.D., Robert Sweet, M.D., Jules Rosen, M.D., Rona E. Pasternak, M.D., and Robert D. Nebes, Ph.D. This study was supported in part by a Merck/AFAR Fellowship in Geriatric Clinical Pharmacology (Dr. LaghrissiThode) and USPHS grants MH..OI040 (Dr. Po/lock) and 30915 (Dr. Kupferf from the National Institute "ofMental Health, Bethesda, MD. References 1. Tinctti ME: Factors associated with serious injury during falls by ambulatory nursing home residents. J Am Gcriatr Soc 1987; 35:644-648 THE AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY 2. Gryfe CIt Anties A, Ashley MJ: A longitudinal study of falls in an elderly population, I: meldence and morbidity. Age Ageing 1977; 227 Sertraline and Nortriptyline 6:201-210 3. So rock GS: Falls among the elderly: epidcmiol.. ogy and prevention. Am J Prey Mcd 1988; 4:282-288 4. Baker SP, HarveyAH: Fall injuries in the elderly. Clin Gcrlatr Med 1985; 1:501-512 5. Murphy J, Issacs B: The post-fall syndrome. Gerontology 1982; 28:265-270 6. Tinctti ME, Spccchley M: Prevention of falls among the elderly. Medical Intelligence 1989; 320: 1055-1059 7. Ray WA, Griffin MR, Schaffner W, et al: Psychotropic drug usc and the risk of hip fracture. N Englj Med 1987; 316:363-369 8. Prudham 0, Evans JG: Factors associated with falls in the elderly: a community study. Age Ageing 1981; 10:141-146 9. MacDonald JB: The role of drugs in falls in the elderly. Clin Geriatr Med 1985; 1:621-636 10. Campbell JA: Drug treatment as a cause of falls in old age. Drugs Aging 1991; 1:289-302 11. Ruthazcr R, Lipsitz LA: Antidepressants and falls among older people in long-term care. Am J Public Health 1993; 83:746-749 12. Ekdahl C, jarnlo GB, Andersson 81: Standing balance in healthy subjects. Scand J Rchabil Mcd 1989; 21:187-195 13. Baloh WB, Fife TO, Z\vcrling L, et al: Compari.. son of static and dynamic posturography in young and older normal people. J Am Geriatr Soc 1994; 42:405-412 14. Ludln T, Grabiner M, Omlid M: Postural control and perceived stability limits in the elderly. Can.. ference Proceedings of the American Society of Biomechanics, 1994 15.Biomcchanics Data-Acquisition and Analysis Software, DEDAS Operating Manual, Advanced Mechanical Technology, Inc., 1991 16. Hufschmidt At Dichangs J, Maurtiz KH, et al: Some methods and parameters of body sway quantification and their neurological applications. Archiv fUr Psychiatric und Nervenkrankheiten 1980; 135-150 17. Vissier H: Gait and balance in senile dementia of Alzheimer's type. Age Ageing 1983; 12:296-301 18. Hasan SS, Lichtenstein Mj, Shiavi RG: Effect of loss of balance on biomechanics platform measures of sway: influence of stance and a method for adjustment. J Biomcch 1990; 23:783-789 19. Ducan G, WilsonjA, MacLcnnan Wj, et al: Clinical correlates of sway in elderly living at home. Gerontology 1992; 38: 160~166 20. Fernie GR, Gryfc CI, Holliday PJ, et al: The relation of postural sway in standing to the incidence of falls in geriatric subjects. Age Ageing 1982; 11:11~16 21.0vcrstall PW, Bxton-Smlth AN, Imms f:J, et al: Falls in the elderly rein ted to postural imbal- 228 ancc. Dr Med J 1977; 1:261-264 22. Pyykko It Jantti P, Anlto H: Postural control in elderly subjects. Age Ageing 1990; 19:215-221 23. Robin D\V, Hasan S5, Lichtenstein MJ, ct al: Dose-related effect of trlazolam on postural sway, Clin Pharmacal Ther 1991; 49:581-588 24. Berlin I, Warot D, Hergueta T t et al: Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J .Clin Psychopharmacol1993; 13:100-106 25. Stevens A, Mulrow C: Drug affecting postural stability and other risk factors in the hip fracture epidemic-case.. ontrol study. Community Medic cine 1989; 11:27-34 26. Guthrie SK, Alexander NB, Schultz AB, et al: Effect of imipramine on postural stability in young and old adults (abstract). Clin Pharmacal Ther 1993; 53: 177 27. McClelland GR: Body sway and the effects of psychoactive drugs: a review, Human Psycho.. pharmacology 1989; 4:3-14 28. Bouchard RH, Pourcher H, Vincent P: Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989; 146:1352-1353 29. Baldessarini RJ,.Marsh fiR: Fluoxetine and side effects. Arch Gcn Psychiatry 1990; 47:191-192 30. Baldessnrini RJ, Marsh sa, Kula NS: Interactions of fluoxctine with metabolism of dopamine and serotonin in rat brain regions. Brain Res 1992; 579:152-156 31. Richelson E: The pharmacology of antidepressants at the synapse: focus on newer com.. pounds. J Clin Psychiatry 1994; 55:9 (Suppl A):34-39 32. Hyttel J: Pharmacological characterization of selective serotonin reuptake inhibitors (SSIUs). Int Clin Pharmacal 1994; 9: 19-26 33. Nakagawa H, Ohashi N, Kanda K, et al: Auto .. nomic nervous system disturbance as etiological background of vertigo and dizziness. Acta Otolaryngologica Supp11993; 504:130-133 34.Ahmad N, Wilson JA, Barr-Hamilton RM, et al: The evaluation of dizziness in elderly patients. Postgrad Mcd J 1992; 68:558-561 35.Trouillns P: The cerebellar serotonlnerglc sys.. tern and its possible involvement in cerebellar ataxia. Can J Neural Sci 1993; 20 Suppl 3:578-582 36. Kish SJ, Robitaille Y, Schut 1.., et al: Normal serotonin but elevated 5-hydroxyindoleacetic acid concentration in cerebellar cortex of patients with dominantly inherited ollvopontocerebellar atrophy. Ncurosci Lett 1992; 144:84-86 37.Miller MD, Pollock BG, RiCai AH: Longitudinal analysis of nortriptyline side effects in elderly depressed patients. J Gcriatr Psychiatry Neural 1991; 4:226-230 VOLUME 3 • NUMBER 3 • SUMMER 1995